depression on tirzepatide Once-weekly subcutaneous was not associated with an increased risk of compared with placebo, according to a post hoc analysis of the SURMOUNT clinical trial programme. The findings were published in Obesity is associated with an
Description
Which medicines interact with Wegovy
People who want a simple, visual food guide
Discover why some patients experience increased sugar cravings during tirzepatide treatment, how blood glucose changes may influence appetite, and evidence-based strategies to manage cravings whilst maintaining diabetes control and weight loss goals.
Administered as a subcutaneous weekly injection, it is a manifold single pharmacological agent that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia favorably modifying the lipid profile
If your doctor recommends the switch from Zepbound to Wegovy, its important to follow a personalized plan for discontinuing Zepbound and starting Wegovy.
Using an approved sharps container helps prevent injury, contamination, and the spread of infection
